Feasability of a Care Pathway Integrating Collaborative Tele-expertise to Prevent Recurring Hospitalisations for Diabetic Patients

Overview

Telemedicine for diabetic patients is currently based simply on remotely monitoring capillary blood glucose levels. This experimental approach remains limited to insulin-treated diabetic patients with sufficient motivation and ability to use connected devices and only considers one aspect of the care required by diabetic patients. So far, telemedicine has not offered a more global approach to the therapeutic support of patients. This failing leads to recurrent hospitalizations for acute metabolic events. This project aims to demonstrate the feasibility of an individualized care pathway based on a multidisciplinary tele-medical network on a territorial scale. This pathway will include a base program with follow-up that can be adapted and revised thanks to the regular use of collaborative tele-expertise. The possibility of monthly multidiciplinary meetings via Tele-expertise between the different diabetes centers of the hospital groups would help to define and implement an individualized care pathway for diabetic patients hospitalized on a recurring basis (≥2 hospitalizations/year), which would be defined collegially during the multidiciplinary meetings .

Full Title of Study: “Evaluation of the Feasability of a Care Pathway Integrating Collaborative Tele-expertise for the Prevention of Recurrent Hospitalisations for Patients With Diabetes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 4, 2024

Detailed Description

Diabetes control, assessed on the level of glycated hemoglobin (HbA1c), improves complications such as microangiopathy. To reduce cardiovascular disease, better global management including an individualized care pathway is required. Inadequate care results in a high rate of re-hospitalizations during the year (approximately 15 to 20% of all diabetic patients). So far, the only contribution of telemedicine in the context of diabetes has been the teletransmission of data from electronic monitoring logs, including insulin doses and capillary blood glucose measurements, to platforms accessible to healthcare teams (physicians and non-medical staff). Remote monitoring according to these methods can lead to asynchronous therapeutic proposals whose effectiveness on HbA1c levels has already been demonstrated and the contribution of telemonitoring has also already been validated on the improvement of certain cardiovascular risk factors. However, this experimental approach remains limited to insulin-treated diabetic patients with sufficient capacity and motivation to use connected devices. It only considers one component of the care required by patients with diabetes. Until now, telemedicine has not proposed a global approach to the therapeutic accompaniment of diabetic patients. Thus, recurrent hospitalizations for acute metabolic events (ketoacidosis, severe hypoglycemia) or complications related to diabetes (severe foot wounds, cardiovascular accidents, visual or renal alterations) are frequently observed. The ambition of our project is therefore to demonstrate the feasibility of setting up an individualized care pathway that can be supported by a multidisciplinary tele-medical network on a regional level. This pathway will include a basic program and a follow-up which can be adapted and revised through regular use of collaborative tele-expertise.

Interventions

  • Other: Definition of the Individualized Care Pathway
    • Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient’s general practitioner (with or without a consultation with the clinical pharmacist).

Arms, Groups and Cohorts

  • Experimental: All patients on the basic diabetic program, eligible for an individualized care pathway.
    • This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients eligible for the Individualized Care Pathway as well as the basic diabetic program.
    • Time Frame: At the end of the study period: Month 12 + 5 days
    • After the intial pre-inclusion visit, 30 days before inclusion, a multidiciplinary tele-expertise meeting will be held to decide which patients are eligible for inclusion in the individualized care pathway. The aim is to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalization, iteratively over the year (≥ 2/year). The feasibility will be assessed by the number of inclusions and the number of patients included who have had at least 3 of the 4 planned follow-up visits.
  • Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits.
    • Time Frame: At the end of the study period: Month 12 + 5 days
    • This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalization, iteratively over the year (≥ 2/year). The feasibility will be assessed by : The number of inclusions and the number of patients included who have completed at least 3 of the 4 planned follow-up visits.

Secondary Measures

  • Evolution of blood glucose (sugar) levels in patients benefitting from the individualized care pathway.
    • Time Frame: Month 0
    • The rate of HbA1c will be measured as a percentage.
  • Evolution of blood glucose (sugar) levels in patients benefitting from the individualized care pathway.
    • Time Frame: Month 3
    • The rate of HbA1c will be measured as a percentage.
  • Evolution of blood glucose (sugar) levels in patients benefitting from the individualized care pathway.
    • Time Frame: Month 6
    • The rate of HbA1c will be measured as a percentage.
  • Evolution of blood glucose (sugar) levels in patients benefitting from the individualized care pathway.
    • Time Frame: Month 9
    • The rate of HbA1c will be measured as a percentage.
  • Evolution of blood glucose (sugar) levels in patients benefitting from the individualized care pathway.
    • Time Frame: Month 12
    • The rate of HbA1c will be measured as a percentage.
  • Re-hospitalization rate
    • Time Frame: 2 years (concernining the period M0 to M12)
    • The SNIIRAM (Système National d’Information Inter Régimes de l’Assurance Maladie) which is the French Health Insurance database, will be used to observe the number of re-hospitalizations throughout the year. For each patient, in the database, YES or NO will be recorded to answer the question: Re-hospitalization? and, if the patient has been re-hospitalized, the number of re-hospitalizations will be noted.
  • Number of incidents of ketoacidosis
    • Time Frame: 2 years (Month -12 to Month 12)
    • The number of serious incidents of ketoacidosis will be noted from data in the patient file.
  • Number of incidents of hypoglycemia
    • Time Frame: 2 years (Month -12 to Month 12)
    • The number of serious incidents of hypoglygemia will be noted from data in the patient file.
  • Number of incidents of serious wounds
    • Time Frame: 2 years (Month -12 to Month 12)
    • The number of serious wounds will be noted from data in the patient file.
  • Number of cardiovascular accidents
    • Time Frame: 2 years (Month -12 to Month 12)
    • The number of cardiovascular accidents will be noted from data in the patient file.
  • Number of incidents of diabetic microangiopathy
    • Time Frame: 2 years (Month -12 to Month 12)
    • The number of incidents of diabetic microangiopathy will be noted from data in the patient file.
  • Cost of care of diabetic patients
    • Time Frame: 2 years (Month -12 to Month 12)
    • The total cost of caring for these diabetic patients who have had unscheduled hospitalization(s) during the year will be measured in Euros. Expenses will include consultations, hospitalizations, drug treatments, etc.). This information will be extracted from the French Health Insurance database (SNIIRAM).
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of centers involved.
    • Time Frame: 1 year (Month 12)
    • Number of centers involved in each multidisciplinary tele-expertise meeting.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise.Number of centers connected.
    • Time Frame: 1 year (Month 12)
    • Number of centers connected at each multidisciplinary tele-expertise meeting.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise.Number of participants connected.
    • Time Frame: 1 year (Month 12)
    • Number of participants per center connected at each multidisciplinary tele-expertise meeting.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Duration of meetings.
    • Time Frame: 1 year (Month 12)
    • Duration of each multidisciplinary tele-expertise meeting in terms of minutes.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise.Technical difficulties.
    • Time Frame: 1 year (Month 12)
    • Number of technical difficulties encountered at each multidisciplinary tele-expertise meeting (connection etc.)
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. New patient files per center.
    • Time Frame: 1 year (Month 12)
    • Number of new patient files presented per center.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Patient follow-up files per center.
    • Time Frame: 1 year (Month 12)
    • Number of patient follow-up files presented per center.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. New patient files at each meeting.
    • Time Frame: 1 year (Month 12)
    • Number of new patient files presented at each multidisciplinary tele-expertise meeting.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Patient follow-up files at each meeting.
    • Time Frame: 1 year (Month 12)
    • Number of patient follow-up files presented at each multidisciplinary tele-expertise meeting.
  • Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of follow-up visits per patient per center.
    • Time Frame: 1 year (Month 12)
    • Number of 3-monthly follow-up visits per patient per centre.

Participating in This Clinical Trial

Inclusion Criteria

  • Diabetic patients hospitalized on an unscheduled basis in the diabetology department of one of the 8 study centers. – Patients with at least two unscheduled hospitalizations in less than one year (i.e. at least one other hospitalization in the last 365 days in addition to the hospitalization on the day of the pre-inclusion visit). – Patient with diabetes for more than one year at the time of inclusion – Patients affiliated to or beneficiary of a health insurance plan. Exclusion Criteria:

  • Patients with significant language barrier – Homeless patients. – Patients in a period of exclusion determined by another study. – Minor patients. – Patients under legal protection, guardianship or curatorship. – Patient for whom it is impossible to give informed information.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Nīmes
  • Collaborator
    • University Hospital, Montpellier
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Anne-Marie GUEDJ, Dr, +33 4.66.68 33.21, anne.marie.guedj@chu-nimes.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.